BioNxt Solutions Gains European Patent Milestone for Innovative Drug Delivery

The Canadian biotechnology firm BioNxt Solutions has reached a significant corporate milestone, receiving positive notifications from two major patent authorities. The European Patent Office and the Eurasian Patent Organization have both indicated their readiness to grant a key patent for the company’s sublingual thin-film drug delivery technology, potentially unlocking access to a multi-billion dollar market.

This patent advancement secures potential intellectual property protection across up to 54 legal jurisdictions, representing a market encompassing nearly one billion people. The protected technology involves a sublingual thin film that delivers the active pharmaceutical ingredient Cladribin directly into the bloodstream through the oral mucosa. This administration method requires no swallowing or water, and preliminary Read more...